Net Loss Per Share

9 Months Ended

Sep. 30, 2025

8. NET LOSS PER SHARE

Net Loss per Share

Basic earnings per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated based on the combined weighted average number of common shares and potentially dilutive shares, which include the assumed exercise of employee stock options, unvested RSUs and unvested PSUs. In computing diluted earnings per share, the Company utilizes the treasury stock method.

Because the Company reports a net loss attributable to common stockholders, basic and diluted net loss per share attributable to common stockholders are the same for both periods presented. All stock options, RSUs and PSUs units were excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact for the three and nine months ended September 30, 2025. The following stock options, RSUs and PSUs outstanding at each period end have been excluded from the calculation of diluted net loss per share because their inclusion would have been antidilutive:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Options to purchase common stock		9,598,962		8,343,751		9,598,962		8,343,751
Restricted stock units		2,758,695		2,267,734		2,758,695		2,267,734
Performance-based restricted stock units		2,089,494		—		2,089,494		—
Total excluded common stock equivalents		14,447,151		10,611,485		14,447,151		10,611,485

Amylyx Pharmaceuticals, Inc. 10-Q